BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 19274666)

  • 1. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
    Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
    Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
    Minner S; Kraetzig F; Tachezy M; Kilic E; Graefen M; Wilczak W; Bokemeyer C; Huland H; Sauter G; Schlomm T
    Hum Pathol; 2011 Dec; 42(12):1946-52. PubMed ID: 21683980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of proto-oncogene c-kit in high risk prostate cancer.
    Di Lorenzo G; Autorino R; D'Armiento FP; Mignogna C; De Laurentiis M; De Sio M; D'Armiento M; Damiano R; Vecchio G; De Placido S
    Eur J Surg Oncol; 2004 Nov; 30(9):987-92. PubMed ID: 15498646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
    Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
    Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.
    Fleischmann A; Schobinger S; Schumacher M; Thalmann GN; Studer UE
    Prostate; 2009 Mar; 69(4):352-62. PubMed ID: 19016478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
    Helfand BT; Mongiu AK; Kan D; Kim DY; Loeb S; Roehl KA; Meeks JJ; Smith ND; Catalona WJ
    BJU Int; 2009 Aug; 104(3):304-9. PubMed ID: 19239451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy.
    DeCastro GJ; McCann T; Benson MC; McKiernan JM
    Urology; 2008 Dec; 72(6):1214-8. PubMed ID: 18597825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer.
    Chan JK; Magistris A; Loizzi V; Lin F; Rutgers J; Osann K; DiSaia PJ; Samoszuk M
    Gynecol Oncol; 2005 Oct; 99(1):20-5. PubMed ID: 16055178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
    Davis JW; Nakanishi H; Kumar VS; Bhadkamkar VA; McCormack R; Fritsche HA; Handy B; Gornet T; Babaian RJ
    J Urol; 2008 Jun; 179(6):2187-91; discussion 2191. PubMed ID: 18423725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification of high-grade prostate cancer treated with antegrade radical prostatectomy with intended wide resection.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Tsukamoto T; Ohkubo Y; Komai Y; Ishikawa Y; Fukui I
    Jpn J Clin Oncol; 2009 Jun; 39(6):387-93. PubMed ID: 19395463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients.
    van den Brûle FA; Waltregny D; Castronovo V
    J Pathol; 2001 Jan; 193(1):80-7. PubMed ID: 11169519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer.
    Yodavudh S; Tangjitgamol S; Puangsa-art S
    J Med Assoc Thai; 2008 May; 91(5):723-32. PubMed ID: 18672639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.